À la une

Clean Mails -February 2024

A comprehensive approach to AAV vector testing

With a growing number of GMP and non-GMP assays and methods for AAV vector testing, Clean Cells continues to show flexibility in development and routine application, having partnered with several organizations worldwide to develop serotype-specific assays. Our ability to generate chimeric AAV with a trusted partner and two detection platforms most notably allow us to quickly develop crucial assays such as replication competent AAV (rcAAV) testing for novel serotypes.

Clean Mails – February 2024

Clean Cells, your partner for single cell cloning to cGMP cell banks

As a contract organization specializing in cGMP cell & virus banking and QC testing, Clean Cells knows the importance of qualitative cell line development. We thus implemented Solentim’s VIPS® PRO, a state-of-the-art single cell cloning platform to isolate potent clones and characterize the monoclonality of biotherapeutics producing cell lines, with an increased traceability as part of a regulatory compliant approach.

Communiqué de presse

Clean Cells lance ses nouvelles suites de production, doublant ses capacités

En passant de cinq à neuf suites de production dans son nouveau bâtiment inauguré en janvier 2023, Clean Cells se met en ordre de marche pour répondre à la demande croissante de production et caractérisation de banques de cellules et de virus.

Clean Mails – October 2023

Increasing biologics manufacturing capacities

With 23+ years of experience handling hundreds of cell and virus models, Clean Cells has positioned itself as a leader in cell and virus banking, providing complementary characterization and storage services. Our state-of-the-art cGMP facility launched earlier this year now welcomes our biologics manufacturing capacities, providing 8 new clean rooms designed for all types of biopharma projects and equiped to meet production specifications for both adherent and suspension cells.


GMP certificate renewal and successful FDA inspection

Quality and regulatory compliance are the pillars of Clean Cells in order to meet the needs of our customers and support them in the successful development of their biological products. 2023 has been full of success for Clean Cells...

Clean Mails – June 2023

Integrated solutions for cell and virus bank manufacturing and characterization

As a GMP-licensed organization, Clean Cells has a stellar track record in biosafety testing and characterization services for various biopharmaceuticals since 2000. Moreover, the company excels in cell and virus bank manufacturing services to produce starting materials for vaccines, monoclonal antibodies, cell and gene therapies, and other biological products for human and animal health.

Clean Mails – April 2023

A new facility to extend biopharma services

Last January, Clean Cells opened its new cGMP-compliant facility, a cutting-edge 5 300 m2 platform which considerably extends biopharma capacities. Additional biologics testing capacity, extended cell and gene therapy services, end-to-end biomanufacturing and storage: Clean Cells’ new site opens a new chapter in the company’s rich history.